These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9474440)

  • 21. Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis.
    Yilmaz Z; Zai CC; Hwang R; Mann S; Arenovich T; Remington G; Daskalakis ZJ
    Schizophr Res; 2012 Sep; 140(1-3):214-20. PubMed ID: 22795368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine D2 receptor imaging and neuroleptic drug response.
    Heinz A; Knable MB; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 11():84-8; discussion 89-93. PubMed ID: 8941175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and pharmacological evaluation of 11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepines with clozapine-like receptor occupancy at dopamine D
    Watanabe H; Ishida K; Yamamoto M; Horiguchi M; Isobe Y
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127563. PubMed ID: 32976928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy.
    Breier A
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():122-5. PubMed ID: 7961555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine, a fast-off-D2 antipsychotic.
    Seeman P
    ACS Chem Neurosci; 2014 Jan; 5(1):24-9. PubMed ID: 24219174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
    Essock SM; Hargreaves WA; Covell NH; Goethe J
    Psychopharmacol Bull; 1996; 32(4):683-97. PubMed ID: 8993092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clozapine administered once versus twice daily: does it make a difference?
    Procyshyn RM; Vila-Rodriguez F; Honer WG; Barr AM
    Med Hypotheses; 2014 Feb; 82(2):225-8. PubMed ID: 24360486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.
    Arranz MJ; Collier DA; Munro J; Sham P; Kirov G; Sodhi M; Roberts G; Price J; Kerwin RW
    Neurosci Lett; 1996 Oct; 217(2-3):177-8. PubMed ID: 8916101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia.
    de Bartolomeis A; Vellucci L; Barone A; Manchia M; De Luca V; Iasevoli F; Correll CU
    Pharmacol Ther; 2022 Aug; 236():108236. PubMed ID: 35764175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of clozapine in the context of dopamine D1-D2 receptor hetero-dimerization--a working hypothesis.
    Dziedzicka-Wasylewska M; Faron-Górecka A; Górecki A; Kuśemider M
    Pharmacol Rep; 2008; 60(5):581-7. PubMed ID: 19066405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal.
    Bürki HR; Eichenberger E; Sayers AC; White TG
    Pharmakopsychiatr Neuropsychopharmakol; 1975 May; 8(3):115-21. PubMed ID: 1241920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms.
    Jones H; Curtis VA; Wright P; Lucey JV
    Am J Psychiatry; 1998 Jun; 155(6):838-40. PubMed ID: 9619161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients.
    Su TP; Malhotra AK; Hadd K; Breier A; Pickar D
    Arch Gen Psychiatry; 1997 Oct; 54(10):972-3. PubMed ID: 9337781
    [No Abstract]   [Full Text] [Related]  

  • 34. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.
    Farde L; Wiesel FA; Nordström AL; Sedvall G
    Psychopharmacology (Berl); 1989; 99 Suppl():S28-31. PubMed ID: 2573104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine.
    Moresco RM; Cavallaro R; Messa C; Bravi D; Gobbo C; Galli L; Lucignani G; Colombo C; Rizzo G; Velonà I; Smeraldi E; Fazio F
    J Psychopharmacol; 2004 Sep; 18(3):355-65. PubMed ID: 15358979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients.
    Farde L; Nordström AL; Nyberg S; Halldin C; Sedvall G
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():67-9. PubMed ID: 7961577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saturation of striatal D(2) dopamine receptors by clozapine.
    Nyberg S; Chou YH; Halldin C
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):11-6. PubMed ID: 12057028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics.
    de Haan L; Lavalaye J; Booij J; Linszen D
    Am J Psychiatry; 2005 Aug; 162(8):1544-5. PubMed ID: 16055785
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of clozapine on self-injurious behavior.
    Hammock RG; Schroeder SR; Levine WR
    J Autism Dev Disord; 1995 Dec; 25(6):611-26. PubMed ID: 8720030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology of N-desmethylclozapine.
    Lameh J; Burstein ES; Taylor E; Weiner DM; Vanover KE; Bonhaus DW
    Pharmacol Ther; 2007 Aug; 115(2):223-31. PubMed ID: 17583355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.